GlassScriptPhysician profile
Amy Marie Yager
NPI 1396996948
$14,748.30
in general payments reported to CMS, 2019-2025
27 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,105 · 2022: $3,402 · 2023: $5,016 · 2024: $3,471 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,660 · Travel and Lodging: $1,438 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,660.11 |
| Travel and Lodging | $1,438.49 |
| Education | $142.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,121.44 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,863.31 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,821.51 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,563.26 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,046.91 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,001.70 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $821.59 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $616.86 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $527.08 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $521.56 | 2021-2025 | Qelbree, Qelbree |
| Harmony Biosciences LLC | $515.31 | 2022-2024 | Wakix |
| Neurocrine Biosciences, INC. | $462.25 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $318.10 | 2021-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $237.40 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $224.41 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $200.68 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $195.34 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $180.63 | 2024 | |
| Bausch Health US, LLC | $162.31 | 2022-2023 | Wellbutrin, Aplenzin |
| Corium, LLC | $67.05 | 2022-2023 | Azstarys |
| Eisai INC. | $62.69 | 2022-2023 | |
| Indivior INC. | $59.35 | 2021-2023 | Perseris |
| Avanir Pharmaceuticals, INC. | $58.08 | 2021-2022 | |
| Brainsway USA INC | $34.08 | 2022 | |
| Biogen, INC. | $26.26 | 2024 | |
| Merck Sharp & Dohme LLC | $24.92 | 2022 | |
| Livanova USA, INC. | $14.22 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.